Siwek Gregory T, Pfaller Michael A, Polgreen Philip M, Cobb Sandra, Hoth Peter, Magalheas-Silverman Margarida, Diekema Daniel J
Program of Hospital Epidemiology, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA.
Diagn Microbiol Infect Dis. 2006 Jul;55(3):209-12. doi: 10.1016/j.diagmicrobio.2006.01.018. Epub 2006 Apr 19.
We performed a retrospective observational study to examine the incidence of invasive aspergillosis (IA) among allogeneic hematopoietic stem cell transplant (HSCT) recipients, according to whether patients received at least 1 week of voriconazole prophylaxis. We report no cases of IA among 92 HSCT recipients who received voriconazole prophylaxis compared with a 10% (23/223) incidence among those receiving other systemic antifungals for prophylaxis (P < .0005).
我们进行了一项回顾性观察研究，以根据患者是否接受了至少1周的伏立康唑预防治疗，来检查异基因造血干细胞移植（HSCT）受者中侵袭性曲霉病（IA）的发生率。我们报告，在接受伏立康唑预防治疗的92例HSCT受者中没有IA病例，而在接受其他全身性抗真菌药物进行预防治疗的患者中，IA发生率为10%（23/223）（P <.0005）。
